RU2016136702A - Клетки для иммунотерапии, сконструированные для нацеливания на антиген, присутствующий одновременно на иммунных клетках и на патологических клетках - Google Patents
Клетки для иммунотерапии, сконструированные для нацеливания на антиген, присутствующий одновременно на иммунных клетках и на патологических клетках Download PDFInfo
- Publication number
- RU2016136702A RU2016136702A RU2016136702A RU2016136702A RU2016136702A RU 2016136702 A RU2016136702 A RU 2016136702A RU 2016136702 A RU2016136702 A RU 2016136702A RU 2016136702 A RU2016136702 A RU 2016136702A RU 2016136702 A RU2016136702 A RU 2016136702A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- paragraphs
- immune
- cell
- stage
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title claims 24
- 210000004027 cell Anatomy 0.000 title claims 16
- 230000001575 pathological effect Effects 0.000 title claims 9
- 239000000427 antigen Substances 0.000 title claims 2
- 108091007433 antigens Proteins 0.000 title claims 2
- 102000036639 antigens Human genes 0.000 title claims 2
- 238000009169 immunotherapy Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims 45
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 230000000890 antigenic effect Effects 0.000 claims 7
- 230000002779 inactivation Effects 0.000 claims 7
- 239000003550 marker Substances 0.000 claims 6
- 102100031780 Endonuclease Human genes 0.000 claims 5
- 108010042407 Endonucleases Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000644 propagated effect Effects 0.000 claims 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 claims 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 102100026549 Caspase-10 Human genes 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100038918 Caspase-6 Human genes 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 1
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 claims 1
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 claims 1
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 claims 1
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 claims 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 claims 1
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 claims 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 1
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 claims 1
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 claims 1
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 claims 1
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 claims 1
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 claims 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 claims 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 claims 1
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 claims 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims 1
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 claims 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 claims 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 claims 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims 1
- -1 SMAD10 Proteins 0.000 claims 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 claims 1
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 claims 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims 1
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 claims 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 claims 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 108091007178 TNFRSF10A Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 claims 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000037353 metabolic pathway Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (48)
1. Способ получения иммунных клеток, предпочтительно Т-клеток, для иммунотерапии против патологических клеток, включающий стадию:
а. Генетического инактивирования или мутирования гена в иммунной клетке, который участвует в экспрессии или презентации антигенного маркера, причем указанный антигенный маркер присутствует на поверхности, как указанной иммунной клетки, так и патологической клетки;
б. Экспрессии в указанной иммунной клетке трансгена, кодирующего химерный антигенный рецептор, направленный против указанного антигенного маркера, присутствующего на поверхности указанной патологической клетки.
2. Способ по п. 1, в котором указанный антигенный маркер выбран из маркеров, перечисленных в таблице 4.
3. Способ по п. 1, в котором указанным антигенным маркером является CD38 или его иммунореактивный фрагмент.
4. Способ по любому из пп. 1-3, где указанный способ включает дополнительную стадию инактивирования и размножения иммунных клеток.
5. Способ по любому из пп. 1-4, где указанный способ включает дополнительную стадию очистки получаемых иммунных клеток путем исключения клеток, презентирующих указанный маркерный антиген на поверхности.
6. Способ по любому из пп. 1-5, где указанный способ включает предшествующую стадию получения иммунных клеток от донора.
7. Способ по любому из пп. 1-5, где указанный способ включает предшествующую стадию получения иммунных клеток от пациента, болезнь которого вызвана развитием указанных патологических клеток.
8. Способ по любому из пп. 1-7, где указанная иммунная клетка является производной первичной стволовой клетки, клетки iPS или hES.
9. Способ по п. 8, в котором указанная иммунная клетка происходит от клетки iPS, полученной от указанного пациента, болезнь которого вызвана развитием указанных патологических клеток.
10. Способ по любому из пп. 1-9, в котором стадию а) осуществляют, используя редкощепящую эндонуклеазу.
11. Способ по п. 10, в котором стадию а) осуществляют, используя TAL-нуклеазу.
12. Способ по п. 10, в котором стадию а) осуществляют, используя РНК-направляемую эндонуклеазу.
13. Способ по п. 12, в котором РНК-направляемой эндонуклеазой является Cas9.
14. Способ по п. 12, в котором РНК-направляемая эндонуклеаза расщепляется по меньшей мере на 2 полипептида, один из которых включает RuvC, а другой включает HNH.
15. Способ по п. 10, в котором указанная эндонуклеаза экспрессируется с трансфецированной мРНК.
16. Способ по любому из пп. 1-15, который включает дополнительную стадию инактивирования гена, кодирующего компонент рецептора Т-клеток (TCR).
17. Способ по п. 16, в котором указанным компонентом рецептора Т-клеток является TCRα.
18. Способ по любому из пп. 1-15, который включает дополнительную стадию инактивирования гена, кодирующего компонент HLA.
19. Способ по любому из пп. 1-15, который включает дополнительную стадию инактивирования гена, кодирующего β2m.
20. Способ по любому из пп. 1-15, который включает дополнительную стадию инактивирования гена, кодирующего белок иммунной контрольной точки, выбранный из CTLA4, РРР2СА, РРР2СВ, PTPN6, PTPN22, PDCD1, LAG3, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, LAIR1, SIGLEC7, SIGLEC9, CD244, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, FOXP3, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2 и GUCY1B3.
21. Способ по п. 20, в котором указанный генный локус участвует в экспрессии генов PD1 или CTLA-4.
22. Способ по любому из пп. 1-15, который включает дополнительную стадию инактивирования гена, определяющего чувствительность иммунных клеток к химиотерапевтическим или иммуносупрессорным лекарственным средствам.
23. Способ по п. 22, в котором указанный дополнительный ген кодирует CD52.
24. Способ по п. 22, в котором указанный дополнительный ген является геном гипоксантингуанин-фосфорибозилтрансферазы (HPRT).
25. Способ по п. 22, в котором указанный дополнительный ген кодирует глюкокортикоидный рецептор (GR).
26. Способ по п. 22, в котором указанный дополнительный ген участвует в регуляторном метаболическом пути DCK, в частности в экспрессии DCK.
27. Способ по любому из пп. 1-26, в котором указанные иммунные клетки на стадии а) являются производными от воспалительных Т-лимфоцитов, цитотоксических Т-лимфоцитов, регуляторных Т-лимфоцитов или Т-лимфоцитов-хелперов.
28. Способ по п. 27, в котором указанные Т-клетки являются производными от CD4+ Т-лимфоцитов и/или CD8+ Т-лимфоцитов.
29. Способ по любому из пп. 1-28, в котором указанные трансформированные иммунные клетки размножают in vitro.
30. Способ по любому из пп. 1-28, в котором указанные трансформированные иммунные клетки размножают in vivo.
31. Способ по любому из пп. 1-30, в котором указанные патологические клетки выбраны из злокачественных или инфицированных клеток.
32. Способ по любому из пп. 1-30, в котором указанные патологические клетки являются В-клетками.
33. Способ по любому из пп. 1-30, в котором указанные патологические клетки являются клетками солидных опухолей.
34. Способ по любому из пп. 1-30 для получения иммунных клеток, используемых в качестве лекарственного средства.
35. Способ по п. 31 для получения иммунных клеток для лечения рака, иммунного заболевания или инфекции у пациента, нуждающегося в таком лечении.
36. Способ по п. 32 для лечения лимфомы.
37. Способ по п. 32 для лечения лейкоза.
38. Способ по п. 34 для лечения хронического лимфоцитарного лейкоза (CLL).
39. Сконструированная иммунная клетка, получаемая способом по любому из пп. 1-35.
40. Сконструированная иммунная клетка по п. 39, получившая фенотип [CAR CD38]+[CD38]-.
41. Сконструированная иммунная клетка по п. 39, получившая фенотип [CAR CD70]+[CD70]-.
42. Сконструированная иммунная клетка по п. 39, получившая фенотип [CAR CS1]+[CS1]-.
43. Способ лечения пациента, включающий:
а. диагностирование указанного пациента на наличие патологических клеток, презентирующих специфические антигенные маркеры подобно иммунным клеткам;
б. получение популяции сконструированных иммунных клеток по пп. 39-42 или способом по любому из пп. 1-35, и
в. введение указанных сконструированных иммунных клеток указанному пациенту, у которого диагностированы указанные патологические клетки.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201470076 | 2014-02-14 | ||
DKPA201470076 | 2014-02-14 | ||
PCT/EP2015/053162 WO2015121454A1 (en) | 2014-02-14 | 2015-02-13 | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016136702A true RU2016136702A (ru) | 2018-03-19 |
RU2016136702A3 RU2016136702A3 (ru) | 2018-08-17 |
RU2714258C2 RU2714258C2 (ru) | 2020-02-13 |
Family
ID=50114255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016136702A RU2714258C2 (ru) | 2014-02-14 | 2015-02-13 | Клетки для иммунотерапии, сконструированные для нацеливания на антиген, присутствующий одновременно на иммунных клетках и на патологических клетках |
Country Status (19)
Country | Link |
---|---|
US (3) | US10836998B2 (ru) |
EP (2) | EP3505623A1 (ru) |
JP (1) | JP6673838B2 (ru) |
KR (1) | KR102157924B1 (ru) |
CN (1) | CN106029875A (ru) |
AU (1) | AU2015216875B2 (ru) |
BR (1) | BR112016017806B1 (ru) |
CA (1) | CA2937711C (ru) |
DK (1) | DK3105317T3 (ru) |
ES (1) | ES2711498T3 (ru) |
HU (1) | HUE041497T2 (ru) |
IL (1) | IL246645B (ru) |
MX (1) | MX2016010345A (ru) |
NO (1) | NO20161276A1 (ru) |
PL (1) | PL3105317T3 (ru) |
PT (1) | PT3105317T (ru) |
RU (1) | RU2714258C2 (ru) |
TR (1) | TR201819571T4 (ru) |
WO (1) | WO2015121454A1 (ru) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012333134B2 (en) | 2011-07-22 | 2017-05-25 | John Paul Guilinger | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
WO2015070083A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine,Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
AU2014351797B2 (en) * | 2013-11-22 | 2021-03-11 | Cellectis | Method of engineering chemotherapy drug resistant T-cells for immunotherapy |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
KR20170032406A (ko) * | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
BR112017001242A2 (pt) * | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
ES2692206T3 (es) | 2014-11-26 | 2018-11-30 | Miltenyi Biotec Gmbh | Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades |
BR112017011893A2 (pt) * | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
KR102329836B1 (ko) | 2015-01-26 | 2021-11-19 | 셀렉티스 | 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS) |
EP3062105A1 (en) * | 2015-02-26 | 2016-08-31 | Université de Bretagne Occidentale (U.B.O.) | Processes for the diagnosis, prognosis and monitoring of the progression of Chronic Lymphoid Leukaemia (CLL) and/or of Systemic Lupus Erythematosus (SLE) using membrane STIM 1 |
SG11201706774WA (en) | 2015-02-27 | 2017-09-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
CN107683333A (zh) | 2015-03-11 | 2018-02-09 | 塞勒克提斯公司 | 用于工程化同种异体t细胞以增加其在患者中的持久性和/或移植成活率的方法 |
CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
WO2017222593A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
US20190365805A1 (en) * | 2015-09-11 | 2019-12-05 | Carina Biotech Pty Ltd | Chimeric antigen receptors and uses thereof |
WO2017053902A1 (en) * | 2015-09-25 | 2017-03-30 | Abvitro Llc | High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences |
AU2016333898B2 (en) | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
CA3001008A1 (en) | 2015-10-05 | 2017-04-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
CA3001859A1 (en) * | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
MA43187B1 (fr) | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
US10941381B2 (en) | 2015-11-19 | 2021-03-09 | Versiti Blood Research Institute Foundation, Inc. | Method of manufacturing dual-specific T-cells for use in cancer immunotherapy |
CN105368859B (zh) * | 2015-11-25 | 2019-10-18 | 王任直 | 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用 |
IL260750B2 (en) | 2016-03-04 | 2024-02-01 | Morphosys Ag | Clinical evaluation of protein-M response in multiple myeloma |
WO2017177175A1 (en) * | 2016-04-07 | 2017-10-12 | The George Washington University | Methods and compositions targeting retroviral latency |
WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
WO2017178586A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
KR20180135460A (ko) * | 2016-04-15 | 2018-12-20 | 자임워크스 인코포레이티드 | 면역치료제를 표적으로 하는 다중-특이적 항원-결합 작제물 |
CN116850305A (zh) * | 2016-05-06 | 2023-10-10 | 朱诺治疗学股份有限公司 | 基因工程化细胞及其制备方法 |
WO2017214569A1 (en) * | 2016-06-09 | 2017-12-14 | Regents Of The University Of Minnesota | Genome-edited nk cell and methods of making and using |
EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018027036A1 (en) * | 2016-08-03 | 2018-02-08 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
BR112019002779A2 (pt) | 2016-08-12 | 2019-05-14 | Toolgen Incorporated | elemento imunorregulador manipulado e imunidade alterada por este |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN109963590B (zh) | 2016-09-02 | 2024-03-15 | 加利福尼亚大学董事会 | 涉及白介素-6受体α结合单链可变片段的方法和组合物 |
JP7148147B2 (ja) | 2016-10-05 | 2022-10-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ブリオスタチン化合物およびその調製方法 |
WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
EP3522936A4 (en) * | 2016-10-10 | 2020-06-24 | The National Institute for Biotechnology in the Negev, Ltd. | MODIFIED NON-CYTOTOXIC CELLS AND THEIR USE |
CN106544321B (zh) * | 2016-10-13 | 2019-01-29 | 北京艺妙神州医疗科技有限公司 | 通用型car-t细胞及其制备方法和用途 |
EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
JP7069152B2 (ja) * | 2016-10-31 | 2022-05-17 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | 遺伝子組換えにより内在性foxp3遺伝子の発現が安定化されたcd4 t細胞を使用した自己免疫疾患の治療方法 |
EP4001437A1 (en) * | 2016-11-07 | 2022-05-25 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for selecting therapy for a cancer patient |
WO2018087285A1 (en) * | 2016-11-10 | 2018-05-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Or10h1 antigen binding proteins and uses thereof |
EP3321280B8 (en) * | 2016-11-10 | 2021-03-10 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases |
KR20240099512A (ko) | 2016-11-22 | 2024-06-28 | 싱가포르국립대학교 | T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단 |
JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 |
JP7516047B2 (ja) * | 2016-11-23 | 2024-07-16 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とcd38阻害剤とを含む医薬組み合わせ物及びその使用方法 |
CN117305250A (zh) * | 2016-12-09 | 2023-12-29 | 昂克医疗有限公司 | 工程化天然杀伤细胞及其用途 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
CN110494451B (zh) * | 2017-01-13 | 2023-12-01 | 塞尔达拉医疗有限责任公司 | 靶向tim-1的嵌合抗原受体 |
US10440535B2 (en) | 2017-01-25 | 2019-10-08 | The George Washington University | System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets |
AU2018225164A1 (en) * | 2017-02-22 | 2019-09-19 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
WO2018156791A1 (en) * | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
EP3589291A4 (en) | 2017-02-28 | 2020-11-25 | Vor Biopharma, Inc. | COMPOSITIONS AND METHODS OF INHIBITION OF LINE-SPECIFIC PROTEINS |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR102687373B1 (ko) | 2017-03-23 | 2024-07-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
CN110869046A (zh) | 2017-03-31 | 2020-03-06 | 塞勒克提斯公司 | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 |
KR102338993B1 (ko) * | 2017-05-08 | 2021-12-14 | 주식회사 툴젠 | 인위적으로 조작된 조작면역세포 |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
IL270415B2 (en) | 2017-05-12 | 2024-08-01 | Crispr Therapeutics Ag | Materials and methods for cell engineering and their uses in immuno-oncology |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
CN106978445A (zh) * | 2017-06-12 | 2017-07-25 | 内蒙古大学 | CRISPER‑Cas9系统介导的山羊EDAR基因敲除的方法 |
SG10202109108UA (en) * | 2017-06-21 | 2021-09-29 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
JP2020529834A (ja) | 2017-06-30 | 2020-10-15 | プレシジョン バイオサイエンシズ,インク. | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
JP2020530277A (ja) | 2017-06-30 | 2020-10-22 | セレクティスCellectis | 反復投与のための細胞免疫療法 |
EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
CN107312800B (zh) * | 2017-08-01 | 2020-02-07 | 北京舜雷科技有限公司 | 能敲低内源性pd-1表达的cik及其制备方法与应用 |
CN107541526B (zh) * | 2017-08-23 | 2019-12-10 | 北京瑞健科技有限公司 | 能敲低内源性ctla4表达的cik及制备方法与应用 |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
AU2018362014A1 (en) * | 2017-11-03 | 2020-05-28 | Sorrento Therapeutics, Inc. | CD38-directed chimeric antigen receptor constructs |
GB201719169D0 (en) | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
CA3086267A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
WO2019149743A1 (en) | 2018-01-30 | 2019-08-08 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
KR20200115596A (ko) | 2018-02-01 | 2020-10-07 | 화이자 인코포레이티드 | Cd70에 특이적인 항체 및 이의 용도 |
WO2019183572A1 (en) * | 2018-03-23 | 2019-09-26 | Refuge Biotechnologies, Inc. | Gene regulation via conditional nuclear localization of gene modulating polypeptides |
CN111954715A (zh) * | 2018-03-29 | 2020-11-17 | 菲特治疗公司 | 工程改造的免疫效应细胞和其用途 |
US20210015869A1 (en) * | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
MX2020010795A (es) | 2018-04-12 | 2021-01-08 | Prec Biosciences Inc | Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos. |
US20210060071A1 (en) * | 2018-04-27 | 2021-03-04 | The Trustees Of The University Of Pennsylvania | Chimeric Antigen Receptor T Regulatory Cells for the Treatment of Atherosclerosis |
SG11202007878UA (en) | 2018-04-27 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Expression of foxp3 in edited cd34+ cells |
CN112105420A (zh) | 2018-05-11 | 2020-12-18 | 克里斯珀医疗股份公司 | 用于治疗癌症的方法和组合物 |
US20220023338A1 (en) * | 2018-05-15 | 2022-01-27 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tumor cell killers and vaccines |
EP3794130A4 (en) | 2018-05-16 | 2022-07-27 | Synthego Corporation | METHODS AND SYSTEMS FOR DESIGN AND USE OF GUIDE RNA |
CA3103610A1 (en) * | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
AU2019287720A1 (en) | 2018-06-14 | 2021-01-14 | Regeneron Pharmaceuticals, Inc. | CD79A chimeric antigen receptors |
CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
US20210275589A1 (en) * | 2018-07-13 | 2021-09-09 | Nanjing Legend Biotech Co. Ltd. | Co-receptor systems for treating infectious diseases |
CN110819589B (zh) * | 2018-08-13 | 2022-10-11 | 上海科技大学 | 一种增强免疫效应细胞功能的方法 |
EP3844187A1 (en) | 2018-08-28 | 2021-07-07 | Vor Biopharma, Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
EP3629021A1 (en) * | 2018-09-26 | 2020-04-01 | Euroimmun Medizinische Labordiagnostika AG | Diagnosis of a neuroautoimmune disease |
CN113164552A (zh) * | 2018-10-04 | 2021-07-23 | 新泽西州立罗格斯大学 | 使用神经介素肽减少2型细胞因子介导的炎症的方法 |
US20220040229A1 (en) * | 2018-10-31 | 2022-02-10 | Humanigen, Inc. | Materials and methods for treating cancer |
WO2020102721A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als) |
US11103533B2 (en) | 2018-11-30 | 2021-08-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD38 immunotherapy |
AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
WO2020191249A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
WO2020194244A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib and dexamethasone |
US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
WO2020194243A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone |
WO2020194245A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone |
CA3135799A1 (en) | 2019-04-03 | 2020-10-08 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
WO2020222176A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
MX2021014103A (es) * | 2019-05-21 | 2021-12-15 | Univ Leland Stanford Junior | Compuestos de briostatina para mejorar la inmunoterapia. |
AU2020291922A1 (en) * | 2019-06-14 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
AU2020334893A1 (en) * | 2019-08-16 | 2022-02-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
MX2022003316A (es) * | 2019-09-18 | 2022-07-11 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38. |
JP2023501506A (ja) * | 2019-11-13 | 2023-01-18 | 上海医薬集団股▲フン▼有限公司 | T細胞機能を改善するtmem59タンパク質二量体またはキメラ発現受容体 |
CA3158118A1 (en) * | 2019-11-13 | 2021-05-20 | Julie Carson | Methods of manufacturing car-t cells |
WO2022250433A1 (ko) * | 2021-05-24 | 2022-12-01 | 주식회사 센트릭스바이오 | Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
WO2021142127A1 (en) * | 2020-01-08 | 2021-07-15 | Board Of Regents, The University Of Texas System | A method of engineering natural killer cells to target cd70-positive tumors |
CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
JP2023519304A (ja) * | 2020-03-27 | 2023-05-10 | ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー | 多発性骨髄腫における免疫療法の標的およびその同定方法 |
CN115777017A (zh) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技(上海)有限公司 | 用于t细胞工程改造的组合物及方法 |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
EP4165171A1 (en) * | 2020-06-12 | 2023-04-19 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
EP4168438A4 (en) | 2020-06-22 | 2024-07-10 | Univ Ramot | MULTIPLE SUBUNIT PROTEIN MODULES, CELLS FOR EXPRESSING THEM AND USES THEREOF |
CN111796101B (zh) * | 2020-07-14 | 2022-08-26 | 汕头市中心医院 | Notch3蛋白表达量检测剂联合cypa蛋白表达量检测剂在预测癌症治疗疗效的用途 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
JPWO2022210487A1 (ru) * | 2021-03-29 | 2022-10-06 | ||
CA3216175A1 (en) * | 2021-04-05 | 2022-10-13 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
CN113671196B (zh) * | 2021-07-29 | 2023-09-12 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
WO2023088440A1 (en) * | 2021-11-18 | 2023-05-25 | Correctsequence Therapeutics | Regeneration of surface antigen-negative cells |
CN114350616A (zh) * | 2022-01-24 | 2022-04-15 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其制备方法和应用 |
WO2023147293A2 (en) * | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars) |
WO2023168087A1 (en) * | 2022-03-04 | 2023-09-07 | Yale University | Methods and compositions for treating and preventing fibrosis |
CN114397464B (zh) * | 2022-03-24 | 2022-06-10 | 天津德祥生物技术有限公司 | 一种红细胞膜碎片与载体的偶联复合物、其偶联方法和应用 |
WO2023194501A1 (en) * | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
CN114569709B (zh) * | 2022-05-05 | 2022-07-12 | 苏州慧疗生物医药科技有限公司 | 高表达adam-28的黑色素瘤自体肿瘤疫苗的制备方法及其应用 |
CN115951055A (zh) * | 2022-12-13 | 2023-04-11 | 广州顺泰生物医药科技有限公司 | 一种癌症相关蛋白及其抗体和应用 |
WO2024154122A1 (en) | 2023-01-18 | 2024-07-25 | Gilboa Therapeutics LTD | Immune cells expressing a complement receptor and uses thereof |
CN118108860A (zh) * | 2024-03-07 | 2024-05-31 | 南京澄实生物医药科技有限公司 | 一种基于FcRn可提高细胞免疫水平的重组疫苗及应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
WO1994024277A1 (en) | 1993-04-13 | 1994-10-27 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
US6642043B1 (en) | 1996-03-12 | 2003-11-04 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
IL151287A0 (en) | 2000-02-24 | 2003-04-10 | Xcyte Therapies Inc | A method for stimulation and concentrating cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
AU2006224248B2 (en) | 2005-03-15 | 2011-01-06 | Cellectis | I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof |
AU2006272634B2 (en) * | 2005-07-26 | 2013-01-24 | Sangamo Therapeutics, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
US20100267145A1 (en) | 2006-06-05 | 2010-10-21 | Hiroshima University | Immunocompetent cell having anti-cd38 antibody on its cell surface |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP4186978A1 (en) * | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
MX342907B (es) * | 2009-05-13 | 2016-10-17 | Genzyme Corp * | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. |
AU2011223547B2 (en) * | 2010-03-04 | 2016-05-05 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD52 |
CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
US20130323214A1 (en) | 2010-10-27 | 2013-12-05 | Stephen M.G. Gottschalk | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
SG190997A1 (en) * | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
DK2694091T3 (da) | 2011-04-05 | 2019-06-03 | Cellectis | Fremgangsmåde til fremstilling af kompakte tale-nukleaser og anvendelse heraf |
JP2014513948A (ja) | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β2ミクログロブリン欠損細胞 |
WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
MX370265B (es) | 2012-05-25 | 2019-12-09 | Cellectis | Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia. |
EP3730512A1 (en) | 2012-07-13 | 2020-10-28 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
WO2014018601A2 (en) | 2012-07-24 | 2014-01-30 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
KR102141259B1 (ko) | 2012-09-04 | 2020-08-05 | 셀렉티스 | 멀티―체인 키메라 항원 수용체 및 그것의 용도들 |
ES2645393T3 (es) | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
HK1249351A2 (zh) * | 2015-05-15 | 2018-10-26 | Oru Kayak Inc | 可折叠船只 |
-
2015
- 2015-02-13 EP EP18194851.4A patent/EP3505623A1/en active Pending
- 2015-02-13 DK DK15706399.1T patent/DK3105317T3/en active
- 2015-02-13 JP JP2016551704A patent/JP6673838B2/ja active Active
- 2015-02-13 PL PL15706399T patent/PL3105317T3/pl unknown
- 2015-02-13 TR TR2018/19571T patent/TR201819571T4/tr unknown
- 2015-02-13 ES ES15706399T patent/ES2711498T3/es active Active
- 2015-02-13 RU RU2016136702A patent/RU2714258C2/ru active
- 2015-02-13 CN CN201580008739.XA patent/CN106029875A/zh active Pending
- 2015-02-13 KR KR1020167025575A patent/KR102157924B1/ko active IP Right Grant
- 2015-02-13 CA CA2937711A patent/CA2937711C/en active Active
- 2015-02-13 EP EP15706399.1A patent/EP3105317B1/en active Active
- 2015-02-13 WO PCT/EP2015/053162 patent/WO2015121454A1/en active Application Filing
- 2015-02-13 US US15/118,801 patent/US10836998B2/en active Active
- 2015-02-13 HU HUE15706399A patent/HUE041497T2/hu unknown
- 2015-02-13 AU AU2015216875A patent/AU2015216875B2/en active Active
- 2015-02-13 PT PT15706399T patent/PT3105317T/pt unknown
- 2015-02-13 BR BR112016017806-8A patent/BR112016017806B1/pt active IP Right Grant
- 2015-02-13 MX MX2016010345A patent/MX2016010345A/es unknown
-
2016
- 2016-07-07 IL IL246645A patent/IL246645B/en active IP Right Grant
- 2016-08-09 NO NO20161276A patent/NO20161276A1/en unknown
-
2020
- 2020-07-27 US US16/939,466 patent/US11692169B2/en active Active
-
2023
- 2023-05-22 US US18/321,481 patent/US20230357719A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102157924B1 (ko) | 2020-10-26 |
RU2016136702A3 (ru) | 2018-08-17 |
TR201819571T4 (tr) | 2019-01-21 |
RU2714258C2 (ru) | 2020-02-13 |
JP2017506636A (ja) | 2017-03-09 |
EP3105317A1 (en) | 2016-12-21 |
AU2015216875A1 (en) | 2016-07-28 |
JP6673838B2 (ja) | 2020-04-01 |
US10836998B2 (en) | 2020-11-17 |
IL246645A0 (en) | 2016-08-31 |
DK3105317T3 (en) | 2019-01-14 |
US20230357719A1 (en) | 2023-11-09 |
IL246645B (en) | 2021-02-28 |
NO20161276A1 (en) | 2016-08-09 |
PL3105317T3 (pl) | 2019-02-28 |
US20180201901A1 (en) | 2018-07-19 |
BR112016017806B1 (pt) | 2023-05-02 |
BR112016017806A2 (pt) | 2017-10-10 |
CA2937711A1 (en) | 2016-07-22 |
PT3105317T (pt) | 2019-02-27 |
AU2015216875B2 (en) | 2021-02-25 |
EP3505623A1 (en) | 2019-07-03 |
US11692169B2 (en) | 2023-07-04 |
CN106029875A (zh) | 2016-10-12 |
HUE041497T2 (hu) | 2019-05-28 |
KR20160138404A (ko) | 2016-12-05 |
EP3105317B1 (en) | 2018-09-19 |
MX2016010345A (es) | 2017-01-23 |
US20200407682A1 (en) | 2020-12-31 |
ES2711498T3 (es) | 2019-05-06 |
WO2015121454A1 (en) | 2015-08-20 |
CA2937711C (en) | 2020-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016136702A (ru) | Клетки для иммунотерапии, сконструированные для нацеливания на антиген, присутствующий одновременно на иммунных клетках и на патологических клетках | |
LaFleur et al. | PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity | |
Pawelec et al. | Myeloid-derived suppressor cells: not only in tumor immunity | |
RU2018107754A (ru) | Клетки для иммунотерапии, созданные для таргетинга антигена cd38 и для инактивации гена cd38 | |
Malaguarnera et al. | The role of immunity in elderly cancer | |
Stienne et al. | Foxo3 transcription factor drives pathogenic T helper 1 differentiation by inducing the expression of eomes | |
Torti et al. | Non-hematopoietic cells in lymph nodes drive memory CD8 T cell inflation during murine cytomegalovirus infection | |
Zhuang et al. | Genome-wide CRISPR screen reveals cancer cell resistance to NK cells induced by NK-derived IFN-γ | |
Haines et al. | Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23 | |
Sutra Del Galy et al. | In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4+ TH1 cell response | |
RU2015153241A (ru) | Способы конструирования высокоактивных т-клеток для иммунотерапии | |
JP2018522907A5 (ru) | ||
JP2017506636A5 (ru) | ||
JP2019531743A (ja) | 改善された免疫細胞療法のための標的指向遺伝子挿入 | |
Yang et al. | Development of a unique epigenetic signature during in vivo Th17 differentiation | |
Chen et al. | Ly49E separates liver ILC1s into embryo-derived and postnatal subsets with different functions | |
Sharrock | Natural killer cells and their role in immunity | |
Tumino et al. | Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells | |
Kavazović et al. | Cheating the hunger games; mechanisms controlling clonal diversity of CD8 effector and memory populations | |
Brown et al. | Lymph node sharing between pancreas, gut, and liver leads to immune crosstalk and regulation of pancreatic autoimmunity | |
Shah et al. | Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes | |
Kim et al. | FTO negatively regulates the cytotoxic activity of natural killer cells | |
Lak et al. | Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy | |
Guo et al. | Mettl3-dependent m6A modification is essential for effector differentiation and memory formation of CD8+ T cells | |
KR20180063847A (ko) | 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도 |